SAN ANTONIO--(BUSINESS WIRE)--America Stem Cell, Inc. (ASC) announced today it has received clearance from FDA for its Phase I/IIa nationwide multi-center dual-umbilical cord transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome.
Help employers find you! Check out all the jobs and post your resume.
